Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial".
Press Release Nov 14 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Leuprolide Acetate injection, a medication used for advanced prostatic cancer treatment. The injection will be manufactured at Zydus's oncology injectable facility in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 13 2025
- Press Release Nov 11 2025
- Press Release Nov 07 2025
- Press Release Nov 06 2025
- Press Release Nov 05 2025
Later from Zydus Lifesciences
- Press Release Nov 25 2025
- Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market
- Press Release Nov 26 2025
- Press Release Nov 27 2025
- Press Release Dec 04 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences